Cite
Eptacog Beta Efficacy in Treating Mild or Moderate Bleeds in Target Joints of Individuals with Hemophilia A or B and Inhibitors in PERSEPT 1
MLA
Mark T Reding, et al. “Eptacog Beta Efficacy in Treating Mild or Moderate Bleeds in Target Joints of Individuals with Hemophilia A or B and Inhibitors in PERSEPT 1.” Blood, vol. 140, Nov. 2022, pp. 5597–99. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........5165acfa7286ae91311397fcb6aeabb4&authtype=sso&custid=ns315887.
APA
Mark T Reding, Maria Elisa Mancuso, Suchitra Acharya, Sanjay Ahuja, Maria Teresa Álvarez-Román, Lisa N Boggio, Meera B. Chitlur, Abraham Salvador Majluf-Cruz, Amy L Dunn, Miguel Escobar, Annie Harroche, Maissaa Janbain, Craig M. Kessler, Philip Maes, Catherine E. McGuinn, Danielle Nance, Ulrike Nowak-Göttl, Robert F. Sidonio, J., Duc Q Tran, … Steven W. Pipe. (2022). Eptacog Beta Efficacy in Treating Mild or Moderate Bleeds in Target Joints of Individuals with Hemophilia A or B and Inhibitors in PERSEPT 1. Blood, 140, 5597–5599.
Chicago
Mark T Reding, Maria Elisa Mancuso, Suchitra Acharya, Sanjay Ahuja, Maria Teresa Álvarez-Román, Lisa N Boggio, Meera B. Chitlur, et al. 2022. “Eptacog Beta Efficacy in Treating Mild or Moderate Bleeds in Target Joints of Individuals with Hemophilia A or B and Inhibitors in PERSEPT 1.” Blood 140 (November): 5597–99. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........5165acfa7286ae91311397fcb6aeabb4&authtype=sso&custid=ns315887.